Crossject has developed a deep pipeline of products that are based on its proprietary needle-free injection system, Zeneo, across a variety of indications, with a focus on emergency-related areas. In addition to avoiding needles, Zeneo provides a simple and quick (~1/10th of a second) delivery of the drug. Recently, the company has added Zeneo Terbutaline for the acute treatment of exacerbations in severe asthmatics. This is a large market (~2.5m in the US) in need of better choices for patie
03 Oct 2017
- Adding asthma
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
- Adding asthma
Crossject SA (ALCJ:PAR) | 0 0 (-3.4%) | Mkt Cap: 38.7m
- Published:
03 Oct 2017 -
Author:
Maxim Jacobs -
Pages:
14
Crossject has developed a deep pipeline of products that are based on its proprietary needle-free injection system, Zeneo, across a variety of indications, with a focus on emergency-related areas. In addition to avoiding needles, Zeneo provides a simple and quick (~1/10th of a second) delivery of the drug. Recently, the company has added Zeneo Terbutaline for the acute treatment of exacerbations in severe asthmatics. This is a large market (~2.5m in the US) in need of better choices for patie